Trial Profile

A Multicenter, Open-label, Randomized Controlled Phase III Clinical Study to Compare the Efficacy and Safety of FS-1502 Versus T-DM1 in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Status: Recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Caxmotabart Entudotin (Primary) ; Trastuzumab emtansine
Indications Advanced breast cancer; HER2 positive breast cancer; Male breast cancer
Focus Therapeutic Use
Sponsors Shanghai Fosun Pharmaceutical Development

14 Aug 2023 All the primary end points except "Progression-Free Survival (PFS) Based on Independent Central Review (ICR)" have been removed and some shifted to secondary end points, thus removing "AR" from trial foci.
14 Aug 2023 Status changed from not yet recruiting to recruiting.
09 Mar 2023 New trial record

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com